$225 Million

Amicus Therapeutics

Follow-on Offering

Lead Manager, July 2017

Amicus Therapeutics
Amicus is a global patient-focused biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (“ERT”) for Fabry disease.